Dr. Marilyn McLaughlin
Claim this profileYork Hospital
Studies Breast Cancer
Studies Multiple Myeloma
4 reported clinical trials
25 drugs studied
Area of expertise
1Breast Cancer
HER2
lymph node
breast
2Multiple Myeloma
Stage III
Stage IV
Affiliated Hospitals
Clinical Trials Marilyn McLaughlin is currently running
Targeted Therapy
for Advanced Stage Cancer
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact TAPUR@asco.org, or if a patient, your nearest participating TAPUR site (see participating centers). \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\* Results in publication or poster presentation format are posted as they become available for individual cohorts at www.tapur.org/news. The results may be accessed at any time. All results will be made available on clinicaltrials.gov at the end of the study. Indexing of available results on PubMed is in progress. \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*
Recruiting1 award Phase 29 criteria
Imlunestrant
for Early Breast Cancer
This trial is testing a new medication called imlunestrant to see if it works better than standard hormone treatments for certain breast cancer patients. The study focuses on patients with early-stage breast cancer that is estrogen receptor positive and HER2 negative, who have already been on hormone therapy for a period of time and are at high risk of their cancer returning. Imlunestrant works by blocking estrogen from helping cancer cells grow.
Recruiting2 awards Phase 36 criteria
More about Marilyn McLaughlin
Clinical Trial Related8 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Marilyn McLaughlin has experience with
- Abemaciclib
- Futibatinib
- Sunitinib
- Regorafenib
- Temsirolimus
- Trastuzumab And Pertuzumab
Breakdown of trials Marilyn McLaughlin has run
Multiple Myeloma
Non-Hodgkin's Lymphoma
Solid Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Marilyn McLaughlin specialize in?
Marilyn McLaughlin focuses on Breast Cancer and Multiple Myeloma. In particular, much of their work with Breast Cancer has involved HER2 patients, or patients who are lymph node.
Is Marilyn McLaughlin currently recruiting for clinical trials?
Yes, Marilyn McLaughlin is currently recruiting for 2 clinical trials in York Maine. If you're interested in participating, you should apply.
Are there any treatments that Marilyn McLaughlin has studied deeply?
Yes, Marilyn McLaughlin has studied treatments such as Abemaciclib, Futibatinib, Sunitinib.
What is the best way to schedule an appointment with Marilyn McLaughlin?
Apply for one of the trials that Marilyn McLaughlin is conducting.
What is the office address of Marilyn McLaughlin?
The office of Marilyn McLaughlin is located at: York Hospital, York, Maine 03909 United States. This is the address for their practice at the York Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.